啟明醫療-B(02500.HK)擬收購MITRALTECH股權及認購可換股貸款
格隆匯12月8日丨啟明醫療-B(02500.HK)發佈公吿，2021年12月7日，公司與Athena Medtech Holding Ltd(作為買方)、Mitraltech Holdings Ltd.(作為目標公司)、目標公司的若干售股股東(作為目標公司售股股東)及MTH Shareholder Representative LLC(作為售股股東代表)訂立股份購買協議，據此，公司同意收購且各目標公司售股股東同意出售目標公司所有已發行及發行在外的股份(不包括公司擁有的股權)。
總交割代價等於1.5億美元，股份購買協議下的代價包括總交割代價及獲利計酬代價，即在實現若干里程碑事件時的或有付款，可能包括監管性二尖瓣獲利計酬代價、監管性三尖瓣獲利計酬代價及最低患者獲利計酬代價。股份購買交割後，公司將通過買方持有目標公司的全部股本。
同日，在訂立股份購買協議的同時，為吸引目標公司訂立股份購買協議並促使股份購買及其項下的其他交易得以完成，公司及公司全資附屬公司啟明香港亦與目標公司及Cardiovalve(為一間於該公吿日期為目標公司的非全資附屬公司，並於交割前將成為目標公司的全資附屬公司)訂立可換股貸款協議，據此，啟明香港同意以可換股貸款的形式向Cardiovalve提供2300萬美元。
目標公司為一間於2016年根據以色列法律註冊成立的私營公司，主要從事醫療器械研發活動。Cardiovalve為一間於2010年根據以色列法律成立的私營公司，總部設在以色列。截至該公吿日期，Cardiovalve(i)由目標公司及目標公司的非全資附屬公司持有約95.96%，及(ii)由三名獨立第三方持有約4.05%(即Gil HaCohen、Marco Papa及Yosef Gross各自持有約1.35%)。交割前，上述(ii)項中的4.05%權益將轉讓給目標公司，從而使Cardiovalve在交割前成為目標公司的全資附屬公司。
董事認為，股份購買將與公司現有的產品佈局產生協同效應，並將進一步鞏固公司在中國乃至全球結構性心臟病領域的領先地位。此符合公司在全球範圍內進行創新和商業化的長期願景。公司相信，Cardiovalve系統將推動啟明進行創新，為全世界的醫生及患者提供更多的創新治療方案。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
